Thus, the prognostic significance of Ki-67 expression varies in different subtypes of lymphoma and in DLBCL and MCL after the introduction of rituximab, which is valuable for individual prognostic evaluation. This evidence concerns the gene MKI67 and mantle cell lymphoma.